Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (4.463)

1

Skin autoimmunity might be associated with increased efficacy of atezolizumab in metastatic urothelial carcinoma : a case report

enthalten in: Croatian medical journal | 2019

von Rkman, D. | Likić, R. | Bebek, M. | +2

2

Ramucirumab as a second line therapy for advanced HCC : a significant achievement or a wasted opportunity for personalised therapy?

enthalten in: Investigational new drugs | 2019

von Roviello, G. | Sohbani, N. | Petrioli, R. | +1

3

Depletion of regulatory FoxP3+ T cells in the pathogenesis of Stevens-Johnson syndrome induced by mogamulizumab

enthalten in: International journal of dermatology | 2019

von Amakata, M. | Teraki, Y.

4

Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors

enthalten in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | 2019

von Lee, J. | Graham, A. | Sion, A.

5

A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma

enthalten in: European journal of cancer (Oxford, England : 1990) | 2019

von Franken, M. | Leeneman, B. | Gheorghe, M. | +3

6

Molecular remissions are observed in chronic adult T-cell leukemia/lymphoma in patients treated with mogamulizumab

enthalten in: Haematologica | 2019

von Cook, L. | Demontis, M. | Sagawe, S. | +10

7

Strong expression of SLAMF7 in natural killer/T-cell lymphoma and large granular lymphocyte leukemia - a prominent biomarker and potential target for anti-SLAMF7 antibody therapy

enthalten in: Leukemia & lymphoma | 2019

von Elmaagacli, A. | Salwender, H. | Jehn, C. | +6

8

Case report : immune-mediated cerebellar ataxia secondary to anti-PD-L1 treatment for lung cancer

enthalten in: The International journal of neuroscience | 2019

von Tan, Y. | Rannikmäe, K. | Steele, N.

9

PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways

enthalten in: Immunity | 2019

von Zhao, Y. | Lee, C. | Lin, C. | +8

CommentIn: Immunity. 2019 Dec 17;51(6):972-974. - PMID 31951541

10

fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification

enthalten in: International journal of cancer | 2019

von Takegawa, N. | Tsurutani, J. | Kawakami, H. | +8

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[447]